CEO Kersten Geert R Buys 100,000 CEL‑SCI Shares Amid 9.8% Weekly Sell‑Off, Signals Bullish Outlook for Struggling Biotech

Insider Confidence in a Volatile Market

On August 25, 2026 Chief Executive Officer Kersten Geert R purchased 100,000 shares of CEL‑SCI Common Stock at $1.38, bringing his post‑transaction holding to 316,142 shares. The purchase was made at a price near the current closing level of $1.48, indicating that the CEO is buying in a market that has recently slid 9.8% for the week and is still 84% below its all‑time high. The trade comes on the back of a steady stream of insider purchases that have seen Geert’s holdings grow from just over 120,000 shares in early 2026 to more than 1.2 million in March 2026, and then a sharp dip to 311,547 shares after a mid‑May transaction. His latest buy suggests he remains bullish on the company’s long‑term trajectory despite the short‑term volatility.

What This Means for Investors

Insider buying is often viewed as a vote of confidence. Geert’s consistent accumulation—particularly the large block of 300,000 shares in mid‑August at $0.01 for options and a $1.04 cash purchase in late June—signals that management believes the current valuation is undervalued. For investors, this may serve as a catalyst for a modest rally, especially if the company can deliver on its immunotherapy pipeline. However, the company’s price has plunged 84% year‑to‑date, and its trailing P/E is negative, reflecting ongoing R&D costs and revenue uncertainty. A bullish insider stance may not be enough to offset these fundamentals, so investors should weigh the CEO’s confidence against the broader biotech risk profile.

Profile of Kersten Geert R

Geert’s trading pattern is characterized by large, infrequent purchases of both options and common stock. The most recent spike—300,000 options at $0.01 in mid‑August—reveals a strategy of acquiring a substantial future stake at minimal cost, likely tied to performance milestones or dilution protection. His cash purchases cluster around key dates: a $5.26 per‑share buy in January, a $6.85 buy in July 2025, and a $1.04 buy in June 2026. This mix suggests a long‑term horizon; he is willing to invest aggressively when the stock dips, reinforcing a “buy‑the‑dip” philosophy. The pattern also indicates that he maintains a sizable block of shares, which could align his interests closely with shareholders and potentially deter hostile takeovers.

Industry Context and Outlook

CEL‑SCI operates in the competitive biotech arena, focusing on immunotherapy. The company’s 52‑week low of $0.89 and a market cap of roughly $24 million underline its status as a small‑cap, high‑risk play. While the CEO’s insider buys are encouraging, the firm’s negative P/E and steep year‑to‑date decline signal that investors should remain cautious. A positive shift in clinical data or a partnership announcement could unlock value, and the CEO’s continued buying might act as a green light for such events. For now, the insider activity offers a glimpse of confidence, but it is one of many factors investors must consider when assessing CEL‑SCI’s future.